News
Children and adolescents with type 2 diabetes had greater reductions in HbA1c with an oral SGLT2 inhibitor compared with ...
1don MSN
Phase III study supports use of canagliflozin for type 2 diabetes in children and adolescents
A Phase III, international, randomized clinical trial assessed the safety and efficacy of canagliflozin for the treatment of ...
Medical Device Network on MSN14d
Medtronic’s MiniMed 780G system gains CE Mark for expanded indications
The LENNY trial highlighted the system's efficacy and safety in children aged two to six years with type 1 diabetes.
Medtronic (NYSE:MDT) announced today that it received CE mark to expand its MiniMed 780G's indications, including for type 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback